These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39172546)

  • 1. A6 HIV Subtype in a Pharmacist-Directed Cabotegravir/Rilpivirine Screening Protocol.
    Fulco PP; Lavoie S
    AIDS Patient Care STDS; 2024 Oct; 38(10):466-467. PubMed ID: 39172546
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine.
    Ripamonti D; Borghetti A; Zazzi M
    J Antimicrob Chemother; 2024 Oct; 79(10):2720-2724. PubMed ID: 39066658
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.
    Mazzitelli M; Avolio A; Carandina R; Parisi S; Wensing A; Cattelan A
    J Antimicrob Chemother; 2024 Aug; 79(8):2074-2076. PubMed ID: 38905150
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
    Scheibe K; Urbańska A; Serwin K; Parczewski M
    Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
    Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
    J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
    Elliot ER; Polli JW; Patel P; Garside L; Grove R; Barnett V; Roberts J; Byrapuneni S; Crauwels H; Ford SL; Van Solingen-Ristea R; Birmingham E; D'Amico R; Baugh B; van Wyk J
    J Infect Dis; 2024 Jul; 230(1):e34-e42. PubMed ID: 39052748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
    Brock JB; Herrington P; Hickman M; Hickman A
    Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Cossu MV; D'Avolio A; Gervasoni C; Giacomelli A; Cattaneo D; Moschese D
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017524. PubMed ID: 38534104
    [No Abstract]   [Full Text] [Related]  

  • 14. Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
    Barnett SK; Armas-Kolostroubis L; Sension M; Riedel DJ
    AIDS; 2022 Aug; 36(10):1475-1476. PubMed ID: 35876710
    [No Abstract]   [Full Text] [Related]  

  • 15. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
    Blackwell CW; López Castillo H
    J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    Jonsson-Oldenbüttel C; Ghosn J; van der Valk M; Florence E; Vera F; De Wit S; Rami A; Bonnet F; Hocqueloux L; Hove K; Ait-Khaled M; DeMoor R; Bontempo G; Latham CL; Gutner CA; Iyer S; Gill M; Czarnogorski M; D'Amico R; van Wyk J
    J Acquir Immune Defic Syndr; 2024 Aug; 96(5):472-480. PubMed ID: 38985445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.